Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Human Immunodeficiency Virus (HIV): early-phase trial registry

7 of 19 indexed Human Immunodeficiency Virus (HIV) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #902 of 28,707 conditions by registered trial count.

19 US clinical trials · 7 currently recruiting · #902 of 28,707 conditions by registered trial count

Human Immunodeficiency Virus (HIV): 19 US clinical trials tracked, 7 recruiting.

Human Immunodeficiency Virus (HIV) is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is AbbVie, running 2 of these trials.

Enrollment posture brief

Registry condition human-immunodeficiency-virus-hiv

OPEN 7 | RECR 37% | LATE 2 | EARLY 7 | RANK #902 | SPON 2

Nearest open-share peer: Binge Eating (37% recruiting · 19 trials)

Amyotrophic Lateral Sclerosi52.6%Anesthesia, Local42.1%Human Immunodeficiency V (th…37%Alcohol Consumption36.8%Attention Deficit Hyperactiv26.3%
Open-enrollment share among volume-matched conditions near Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV) lists 7 open slots (37% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Human Immunodeficiency Virus (HIV) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Human Immunodeficiency Virus (HIV) is recruiting below its size-band peers.

    7 of 19 indexed trials (36.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Human Immunodeficiency Virus (HIV) trials is spread across many organizations.

    AbbVie accounts for 2 of 19 trials (10.5%). 16 distinct sponsors appear on at least one study for this condition label.

  3. Typical Human Immunodeficiency Virus (HIV) enrolment sits around 124 participants.

    Median target enrolment is 124 among the 19 trials that report a genuine target (sentinel values excluded). 8 of those (42.1%) plan for fewer than 100 participants.

  4. Human Immunodeficiency Virus (HIV) research is mostly interventional.

    17 interventional and 2 observational studies make up this index (89.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 22Phase 31Phase 41

Open and recent trials

19 total, page 1 of 1

RECRUITING Phase 3 4,390 participants

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Merck Sharp & Dohme

NCT07044297

RECRUITING NA 2,000 participants

Persuasive Health Communication Intervention for HIV/HCV

Icahn School of Medicine at Mount Sinai

NCT05968573

RECRUITING Phase 4 500 participants

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

New York University

NCT06598397

RECRUITING NA 314 participants

Quitting Matters Human Immunodeficiency Virus Hybrid Trial

Wake Forest University Health Sciences

NCT06883097

RECRUITING NA 200 participants

e-HERO: Ending the HIV Epidemic in Rural Oklahoma

Northern Arizona University

NCT05664802

RECRUITING NA 189 participants

Project neuroARTEMIS

Wake Forest University Health Sciences

NCT06814275

RECRUITING NA 124 participants

The Trans-Led Care Study

Illinois Institute of Technology

NCT06880705

ACTIVE NOT RECRUITING NA 752 participants

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

April M Young

NCT05657106

COMPLETED 143 participants

New Strategies to Assess Anal Cancer Risk In Women

Emory University

NCT02873741

COMPLETED Phase 2 136 participants

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

PATH

NCT02165202

COMPLETED 100 participants

Evaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents

St. Jude Children's Research Hospital

NCT01849393

COMPLETED Phase 1 65 participants

Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults

U.S. Army Medical Research and Development Command

NCT05423418

COMPLETED NA 61 participants

Tesamorelin Effects on Liver Fat and Histology in HIV

Massachusetts General Hospital

NCT02196831

COMPLETED Phase 1 54 participants

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

AbbVie

NCT04554966

COMPLETED Phase 2 48 participants

Romidepsin Plus 3BNC117 Phase 2a Study

Rockefeller University

NCT02850016

COMPLETED Phase 1 41 participants

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

AbbVie

NCT04223804

COMPLETED Phase 1 15 participants

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Janssen Research & Development

NCT05197075

COMPLETED Phase 1 14 participants

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Merck Sharp & Dohme

NCT06783192

COMPLETED NA 11 participants

Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission

Johns Hopkins University

NCT01053741

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Human Immunodeficiency Virus (HIV) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
MK-8527 Drug
2 trials
Placebo for ABBV-382 Drug
1 trials
ABBV-382 Drug
1 trials
tesamorelin Drug
1 trials
Rilpivirine Drug
1 trials
Radiolabeled Normosol-R Biological
1 trials
Radiolabeled autologous seminal fluid Biological
1 trials

US sites by state

Facility locations filed on Human Immunodeficiency Virus (HIV) trials. A trial with sites in several states counts in each.

New York 6 trials
Georgia 4 trials
Florida 4 trials
New Jersey 3 trials
North Carolina 3 trials
Maryland 3 trials
California 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Human Immunodeficiency Virus (HIV) page

19 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 7 Human Immunodeficiency Virus (HIV) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • AbbVie sponsors the most Human Immunodeficiency Virus (HIV) trials on record, review their full trial history before evaluating a specific study. See AbbVie's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Human Immunodeficiency Virus (HIV) condition card totals 19 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.